meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">platinum-based chemotherapy</span>
<span style="margin-left: 2em;">platinum derivate</span>
<span style="margin-left: 3em;">platinum association</span>
<span style="margin-left: 4em;">pemetrexed plus platin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">Immune checkpoint association</span>
<span style="margin-left: 2em;">nivolumab plus ipilimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
TRAE (any grade) (1)
TRAE leading to discontinuation (grade 3-4) (1)
TRAE (grade 3-4) (1)
TRAE leading to discontinuation (any grade) (1)
STRAE (any grade) (1)
STRAE (grade 3-4) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Constipation TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
pemetrexed plus platin
nivolumab plus ipilimumab
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
pemetrexed plus platin
nivolumab plus ipilimumab
pemetrexed plus platin
---
NA
nivolumab plus ipilimumab
NA
---
pathologies: 173 - treatments: 416,864
result logic
×
Study list
